CD8A and neoplasm: Previously, many studies of preclinical models in lung, colon, and liver cancers have indicated complement-derived inflammatory mediators, such as C5a, together with PD-1 blockade markedly reduced tumor growth and metastasis and lead to prolonged survival via enhancing antitumor CD8+ T cell responses [18–20].